Azetukalner (XEN1101)
Focal Onset Seizures
Key Facts
About Xenon Pharmaceuticals
Xenon Pharmaceuticals is a Canadian biotech leader dedicated to developing life-changing medicines for neurological and psychiatric conditions. Its core strategy leverages a validated human genetics platform to de-risk ion channel drug discovery, resulting in a deep pipeline of 23 candidates, most notably the Phase 3 Kv7 opener azetukalner for epilepsy and depression. With a market cap of $5.23B and a seasoned leadership team, Xenon is transitioning from a discovery-focused entity to a late-stage clinical company with significant near-term catalysts.
View full company profileAbout Xenon Pharmaceuticals
Xenon Pharmaceuticals is a Canadian biotech leader dedicated to developing life-changing medicines for neurological and psychiatric conditions. Its core strategy leverages a validated human genetics platform to de-risk ion channel drug discovery, resulting in a deep pipeline of 23 candidates, most notably the Phase 3 Kv7 opener azetukalner for epilepsy and depression. With a market cap of $5.23B and a seasoned leadership team, Xenon is transitioning from a discovery-focused entity to a late-stage clinical company with significant near-term catalysts.
View full company profileAbout Xenon Pharmaceuticals
Xenon Pharmaceuticals is a Canadian biotech leader dedicated to developing life-changing medicines for neurological and psychiatric conditions. Its core strategy leverages a validated human genetics platform to de-risk ion channel drug discovery, resulting in a deep pipeline of 23 candidates, most notably the Phase 3 Kv7 opener azetukalner for epilepsy and depression. With a market cap of $5.23B and a seasoned leadership team, Xenon is transitioning from a discovery-focused entity to a late-stage clinical company with significant near-term catalysts.
View full company profileTherapeutic Areas
Other Focal Onset Seizures Drugs
| Drug | Company | Phase |
|---|---|---|
| PRAX-628 | Praxis Precision Medicines | Phase 3 |